Paliperidone-ER: first atypical antipsychotic with oral extended release formulation

References

• Aravagiri M, Marder SR. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology159, 424–431 (2002).
   PubMed Web of Science ®Google Scholar
• Swanson J, Gupta S, Lam A et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch. Gen. Psychiatry60(2), 204–211 (2003).
   PubMed Web of Science ®Google Scholar
• Palangio M, Northfelt DW, Portenoy RK et al. Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J. Pain Symptom Manage.23, 355–368 (2002).
   PubMed Web of Science ®Google Scholar
• Conley R, Sathyan G, Prosser J, Gupta SK. Review of the clinical spectrum of the osmotic-controlled release oral delivery system (OROS®) and application in central nervous system disorders. Presented at: Collegium Internationale Neuro-Psychopharmacologicum 25th Biennial Congress. Chicago, IL, USA, 9–13 July 2006.
   Google Scholar
• Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry55(Suppl.), 5–12 (1994).
   PubMed Web of Science ®Google Scholar
• Megens AA, Awouters FH, Schotte A et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology114(1), 9–23 (1994).
   PubMed Web of Science ®Google Scholar
• Karlsson P, Dencker E, Nyberg S et al. Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone ER in healthy subjects. Presented at: European College of Neuropsychopharmacology Congress. Amsterdam, The Netherlands, 21–25 October 2005 (Poster).
   Google Scholar
• Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn-Schmiedeberg’s Arch. Pharmacol.359, 147–151 (1999).
   Google Scholar
• Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet.60, 284–295 (1997).
   PubMed Web of Science ®Google Scholar
• Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology147, 300–305 (1999).
   PubMed Web of Science ®Google Scholar
• Berecz R, Llerena A, de la Rubia A et al. Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry35, 231–234 (2002).
   PubMed Web of Science ®Google Scholar
• Mihara K, Kondo T, Yasui-Furukori N et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther. Drug Monit.25(3), 287–293 (2003).
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Mihara K, Kondo T et al. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J. Clin. Pharmacol.43(2), 122–127 (2007).
   Google Scholar
• Vermeir M, Boom S, Naessens I, Talluri K, Eerdekens M. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Presented at: European College of Neuropsychopharmacology Congress. Amsterdam, Netherlands, 21–25 October 2005 (Abstract).
   Google Scholar
• Goff DC, Cather C, Evins AE et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J. Clin. Psychiatr.66, 183–194 (2005).
   PubMed Web of Science ®Google Scholar
• Gagnon D, Adriaenssen I, Nasrallah H, Morosini PL. Reliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with stable schizophrenia. Presented at: Collegium Internationale Neuro-Psychopharmacologicum 25th Biennial Congress. Chicago, IL, USA, 9–13 July 2006 (Abstract).
   Google Scholar
• Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand.101, 323–329 (2000).
   PubMed Web of Science ®Google Scholar
• Kane J, Canas F, Kramer M et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial, Schizophr. Res.90, 147–161 (2007)
   PubMed Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M et al. Efficacy, safety and effect on functioning of paliperidone extended-release tablets in schizophrenia: an international 6-week placebo-controlled study. Schizophr. Res.93, 117–130 (2007).
   PubMed Web of Science ®Google Scholar
• Marder SR, Kramer M, Ford L et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol. Psychiatry62, 1363–1370 (2007).
   PubMed Web of Science ®Google Scholar
• Swartz MS, Perkins OD, Stroup TS et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry164(3), 428–436 (2007).
   PubMed Web of Science ®Google Scholar
• Meltzer H, Kramer M, Gassmann-Mayer C, Lim P, Bobo W, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies. Presented at: Collegium Internationale Neuro-Psychopharmacologicum 25th Biennial Congress. Chicago, IL, USA, 9–13 July 2006.
   Google Scholar
• Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am. J. Psychiatry162, 1010–1012 (2005).
   PubMed Web of Science ®Google Scholar
• Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum. Psychopharmacol.21, 529–532 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer J, Kramer M, Kostic D, Lane R, Lim P, Eerdekens MM. Metabolic outcomes in patients with schizophrenia treated with oral paliperidone extended-release tablets: pooled analysis of three 6-week placebo-controlled studies. Presented at: Collegium Internationale Neuro-Psychopharmacologicum 25th Biennial Congress. Chicago, IL, USA, 9–13 July 2006.
   Google Scholar
• Kramer M, Simpson G, Maciulis V et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia. A randomized, double-blind, placebo-controlled study J. Clin. Psychopharmacol.27, 6–14 (2007).
   PubMed Web of Science ®Google Scholar
• Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. A six-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients. Presented at: American Psychiatric Association Congress. Toronto, Canada, 20–25 May 2006.
   Google Scholar
• De Deyn PP, Buitelaar J. Risperidone in the management of agitation and aggression associated with psychiatric disorders. Eur. Psychiatry21, 21–28 (2006).
   PubMed Web of Science ®Google Scholar
• Bass DM, Prevo M, Waxman DS. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS): a retrospective study. Drug Saf.25(14), 1021–1033 (2002).
   PubMed Web of Science ®Google Scholar